Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358257 | 1.00 | PTGS1 (0.66) | PTGS1MEN1KMT2ACYP2D6ALOX5 | |
| SCHEMBL123764 | 0.94 | PTGS1 (0.58) | PTGS1MEN1KMT2ACYP2D6ALOX5 | |
| SCHEMBL11063307 | 0.94 | PTGS1 (0.56) | PTGS1MEN1KMT2ACYP2D6ALOX5 | |
| SCHEMBL30345552 | 0.94 | PTGS1 (0.56) | PTGS1MEN1KMT2ACYP2D6ALOX5 | |
| SCHEMBL15849013 | 0.91 | PTGS1 (0.55) | PTGS1MEN1KMT2ACYP2D6ALOX5 | |
| SCHEMBL8636829 | 0.90 | PTGS1 (0.54) | PTGS1MEN1KMT2ACYP2D6ALOX5 | |
| Diphenylether SCHEMBL28334518 | 0.87 | LTA4H (0.60) | PTGS1MEN1KMT2ACYP2D6ALOX5 | |
| SCHEMBL14020499 | 0.86 | SMN1; SMN2 (0.58) | PTGS1MEN1KMT2ACYP2D6ALOX5 | |
| SCHEMBL257802 | 0.86 | ALDH1A1 (0.53) | PTGS1MEN1KMT2ACYP2D6ALOX5 | |
| SCHEMBL9703616 | 0.85 | PTGS1 (0.53) | PTGS1MEN1KMT2ACYP2D6ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670446-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | claimed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023142996-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | 上海岸阔医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | disclosed |
| EP-1469831-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A SOLID AMORPHOUS DISPERSION OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1401399-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003063832-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A SOLID AMORPHOUS DISPERSION OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003000226-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-0531715-B1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL CO (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5426237-A | Oxidation of straight, branched or cyclic alkanes and benzene derivatives in presence of transition metal catalyst and aldehyde | SUMITOMO CHEMICAL CO., LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
| EP-0531715-A1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | PTGS1 1431/4885MEN1 2072/4885KMT2A 3333/4885 |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | PTGS1 737/4885MEN1 4787/4885KMT2A 4246/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | PTGS1 3571/4885MEN1 4272/4885KMT2A 545/4885 |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | LIMK1, LIMK2, ROCK1 | PTGS1 186/4885MEN1 763/4885KMT2A 2416/4885 |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | AAAS, PROC, AADAC | PTGS1 1090/4885MEN1 3636/4885KMT2A 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.